NASDAQ:GMTX Gemini Therapeutics (GMTX) Stock Price, News & Analysis $80.01 -0.58 (-0.72%) As of 08/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock About Gemini Therapeutics Stock (NASDAQ:GMTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gemini Therapeutics alerts:Sign Up Key Stats Today's Range$79.41▼$81.3250-Day Range$65.80▼$81.2152-Week Range$1.16▼$14.10Volume340,964 shsAverage Volume189,291 shsMarket Capitalization$3.47 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents. Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options. In preclinical studies, Gemini’s integrin‐targeting antibodies have shown the ability to reduce tissue scarring and preserve organ function. The company is advancing its most advanced candidates toward investigational new drug (IND) applications, while also exploring additional indications in ocular and hepatic fibrosis where integrin biology may offer therapeutic benefit. Headquartered in Cambridge, Massachusetts, Gemini Therapeutics was founded by a team of scientists and industry veterans with deep expertise in antibody engineering, fibrosis biology and clinical development. The company’s leadership includes professionals with prior experience at leading biopharmaceutical firms and academic institutions. Gemini collaborates with academic research centers and contract research organizations in North America and Europe to support preclinical and clinical programs, with the goal of bringing novel anti‐fibrotic therapies to patients worldwide.AI Generated. May Contain Errors. Read More Receive GMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMTX Stock News HeadlinesFDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026 | cnbc.comWhat Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 14 at 1:00 AM | Porter & Company (Ad)Gemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | washingtonpost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoFebruary 26, 2024 | nypost.comN(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelJune 24, 2023 | benzinga.comSee More Headlines GMTX Stock Analysis - Frequently Asked Questions How have GMTX shares performed this year? Gemini Therapeutics' stock was trading at $79.41 at the beginning of 2026. Since then, GMTX stock has increased by 1.5% and is now trading at $80.59. How were Gemini Therapeutics' earnings last quarter? Gemini Therapeutics, Inc. (NASDAQ:GMTX) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. How do I buy shares of Gemini Therapeutics? Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gemini Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Communications (ZM), Fiverr International (FVRR) and Company Calendar Last Earnings11/15/2021Today8/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMTX CIK1816736 Webwww.geminitherapeutics.com Phone415-877-4887FaxN/AEmployees30Year Founded2015Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$71.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.78% Return on Assets-35.88% Debt Debt-to-Equity RatioN/A Current Ratio71.49 Quick Ratio71.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book27.89Miscellaneous Outstanding Shares43,328,000Free Float37,739,000Market Cap$3.49 billion OptionableNot Optionable Beta-0.12 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:GMTX) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defe...Decentralized Masters | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts